Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0196
Trial ID NCT02070406
Disease Liposarcoma | Peripheral Nerve Sheath Neoplasm | Synovial Sarcoma | Osteosarcoma
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment NY-ESO-1 TCR-T cells
Co-treatment dendritic cell vaccine therapy|fludeoxyglucose F 18
HLAHLA-A*02:01
PhasePhase1
Recruitment statusTerminated
TitleNY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
Year2014
CountryUnited States
Company sponsorJonsson Comprehensive Cancer Center
Other ID(s)13-001624|NCI-2014-00221|13-001624|P30CA016042
Vector information
Vectorretrovirus
Transgene/Inserted geneanti-ESO-1 gene

Clinical Result

Cohort1: liposarcoma
Administration route infusion
Dosage 7.7E8 cells
Donor type autologous
Pts 1
Age Child, Adult, Older_Adult
Lymph depletion Yes
Adverse reactions none(grade 3 or higher)
References PMID: 30573690
Cohort2: Malignant Peripheral Nerve Sheath Tumor
Administration route infusion
Dosage 1E9 cells
Donor type autologous
Pts 1
Age Child, Adult, Older_Adult
Lymph depletion Yes
Adverse reactions none(grade 3 or higher)
References PMID: 30573690
Cohort3: synovial sarcoma
Administration route infusion
Dosage 1E9 cells
Donor type autologous
Pts 3
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 1/3(CR); 1/3(PR)
Adverse reactions none(grade 3 or higher)
References PMID: 30573690
Cohort4: osteosarcoma
Administration route infusion
Dosage 1E9 cells
Donor type autologous
Pts 1
Age Child, Adult, Older_Adult
Lymph depletion Yes
Adverse reactions none(grade 3 or higher)
References PMID: 30573690

Relationship Graph

Overview of Knowledge Graph